Respiratory Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030

Respiratory Disease Testing Market By Product Type (Instruments And Reagents & Kits), Test Type (Imaging, In Vitro Diagnostics, Mechanical Test, And Blood Gas Test), Disease (Lung Cancer, Tuberculosis, Asthma And COPD, And Others), End-User (Hospitals & Clinics, Diagnostics Centre, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing increasing prevalence of respiratory disorders around the globe and increasing risk factors associated with the respiratory disorders.

The respiratory disease testing market was valued at USD 6.40 billion in 2023, growing at a CAGR of 4.29% during the forecast period from 2024 to 2030 to reach USD 8.55 billion by 2030. The demand for respiratory disease testing is primarily being boosted by the rising prevalence of respiratory disorders around the globe. Additionally, increasing risk factors associated with respiratory disorders and increasing product development and approval activities are some of the key factors, which are contributing to the growth of the respiratory disease testing market during the forecast period from 2024 to 2030.

Respiratory Disease Testing Market Dynamics:

According to the data provided by the World Health Organization 2023, around 262 million people are suffering from asthma, globally. Additionally, as per the Asthma and Allergy Foundation of America 2023, more than 27 million people in the United States suffer from asthma, which is equal to 1 in 12 people.

Further, as per the data provided by the Globocan 2022, it was estimated that there were around 2,480,675 people were suffering from lung, bronchus and trachea cancer in the year 2022, globally. As more people suffer from respiratory conditions, there is a greater need for diagnostic tools to accurately identify these conditions. This includes spirometry, imaging tests, blood tests, and other pulmonary function tests. Thus, the growing prevalence of respiratory disorders will drive the market for respiratory disease testing during the forecast years.

Additionally, another driver for the respiratory disease testing market is the increasing risk factors that are contributing to the growing prevalence of respiratory disorders. Exposure to outdoor air pollutants such as particulate matter (PM), nitrogen dioxide (NO2), sulfur dioxide (SO2), and ozone (O3) is a major risk factor for respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), and lung cancer. Additionally, exposure to dust, chemicals, fumes, and other hazardous substances in workplaces, such as in construction, mining, and manufacturing industries, increases the risk of developing respiratory diseases. Further, smoking is the leading cause of COPD and a major risk factor for lung cancer. Both active smoking and secondhand smoke exposure significantly increase the risk of respiratory diseases. According to the Centers for Disease Control and Prevention 2021, nearly 12 of every 100 U.S. adults aged 18 years or older (11.5%) smoked cigarettes. This means an estimated 28.3 million adults in the United States are currently smoking cigarettes. Thus, the increasing risk factors associated with respiratory disorders are likely to drive the growth of the respiratory disease testing market during the forecast period.

However, the high cost associated with respiratory diagnostics devices and stringent regulatory approvals for devices are some of the key constraints that may limit the growth of the respiratory disease testing market.

Respiratory Disease Testing Market Segment Analysis:

Respiratory Disease Testing Market by Product Type (Instruments and Reagents & Kits), Test Type (Imaging, In-vitro Diagnostics, Mechanical Test, and Blood Gas Test), Disease (Lung Cancer, Tuberculosis, Asthma & COPD, and Others), End-User (Hospitals & Clinics, Diagnostics Centre, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the respiratory disease testing market, the instrument category is estimated to amass a significant revenue share in the respiratory disease testing market in 2023. This can be attributed to the various applications of instruments that will be responsible for driving the demand for the respiratory disease testing market during the given forecast period. The instruments form the basis of any respiratory disease testing test, which can be in the form of flow sensors, orchestrators, analyzers, spirometers, X-rays, CT Scanners, and PET/CT devices, among others. For respiratory disease testing, the kits and reagents of the particular test are loaded onto the instrument through which it showcases results, thus indicating the presence of a respiratory disease. Additionally, advanced instruments enable early detection of respiratory diseases, often before symptoms become severe. Early diagnosis is critical for conditions like chronic obstructive pulmonary disease (COPD) and asthma, as it allows for timely intervention and better management.

In addition, the various product launches and regulatory approvals for respiratory disease testing are also expected to propel the market for instruments in the upcoming years. For example, in March 2024, QIAGEN Frankfurt Prime Standard announced the release of the QIAstat-Dx Analyzer 2.0, a prominent upgrade to the widely-used QIAstat-Dx Analyzer 1.0 for accurate, fast, and cost-effective diagnosis of complex syndromes including respiratory diseases.

Therefore, owing to the above-mentioned factors, the instruments category is expected to register significant growth, thereby driving the growth of the overall respiratory disease testing market during the forecast period.

North America Is Expected To Dominate The Overall Respiratory Disease Testing Market:

North America is expected to account for the highest proportion of the respiratory disease testing market in 2023, out of all regions. This is due to the growing prevalence of respiratory diseases in the region. Additionally, increasing risk factors associated with respiratory disorders, the presence of robust research and development initiatives, and a highly viable market in terms of product development, and launches are some of the key factors driving the growth of the respiratory disease testing market in North America.

According to the data provided the Asthma and Allergy Foundation of America (AAFA) 2023, around 38.7% of children below the age of 18 years, had reported having asthma attacks in 2021, in the United States.

Further, according to data provided by the American Society of Cancer 2023, it was estimated that there were around 2,38,340 new cases of lung cancer in the United States in 2023.
Thus, the increasing prevalence of respiratory disorders will create a need for the diagnosis of such respiratory disorders, thus contributing to the growing market demand for respiratory disease testing in the United States, which will in return propel the market for North America respiratory disease testing.

Further, various key product launches in the region are some of the other factors that are influencing the positive growth of the market in North America. For Instance, in August 2023, BD received the U.S. Food and Drug Administration (FDA) clearance for its BD Respiratory Viral Panel (RVP) for BD MAX™ System. This innovative single molecular diagnostic combination test swiftly identified and differentiated SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in roughly two hours.

Therefore, the factors mentioned above, are some of the important factors that are thereby responsible for driving the overall market for respiratory disease testing in North America during the forecast period.

Respiratory Disease Testing Market Key Players:

Some of the key market players operating in the respiratory disease testing market include Koninklijke Philips N.V., Niterra Co., Ltd., Thermo Fisher Scientific Inc., QIAGEN, Abbott, Danaher Corporation, Siemens Healthineers, Diasorin S.p.A, BD, GE Healthcare, QuantuMDx Group Ltd., BIOMÉRIEUX, SDI Diagnostics, COSMED srl, Seegene Inc., CAREstream Medical Ltd., Bird Healthcare, visby medical, Vitalograph, Bio-Rad Laboratories, Inc., and others.

Recent Developmental Activities In The Respiratory Disease Testing Market:

• In July 2023, United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, introduced Next-Generation PET/CT Systems and Integrated Molecular Technology at SNMMI.
• In March 2021, Abbott announced the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its Alinity™ m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) in one test.

Key Takeaways From The Respiratory Disease Testing Market Report Study

• Market size analysis for current respiratory disease testing market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the respiratory disease testing market.
• Various opportunities available for the other competitors in the respiratory disease testing market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current respiratory disease testing market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for respiratory disease testing market growth in the coming future?

Target Audience Who Can Be Benefited From This Respiratory Disease Testing Market Report Study

• Respiratory disease testing product providers
• Research organizations and consulting companies
• Respiratory disease testing- related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in respiratory disease testing
• Various end-users who want to know more about the respiratory disease testing market and the latest technological developments in the respiratory disease testing market.

Frequently Asked Questions For The Respiratory Disease Testing Market:

1. What is meant by respiratory disease testing?

Respiratory disease testing encompasses a range of diagnostic methods and tools used to evaluate lung function, detect respiratory conditions, and monitor the progression of diseases affecting the respiratory system. These tests are crucial for diagnosing, managing, and treating various respiratory disorders.

2. What is the market for respiratory disease testing?

The respiratory disease testing market was valued at USD 6.40 billion in 2023, growing at a CAGR of 4.29% during the forecast period from 2024 to 2030 to reach USD 8.55 billion by 2030.

3. What are the drivers for the global respiratory disease testing market?

The respiratory disease testing market is slated to witness prosperity owing to factors such as the increasing prevalence of respiratory disorders around the globe. Additionally, increasing risk factors associated with respiratory disorders and increasing product development and approval activities are some of the key factors, which are contributing to the growth of the respiratory disease testing market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the global respiratory disease testing market?

Some of the key market players operating in the respiratory disease testing market include Koninklijke Philips N.V., Niterra Co., Ltd., Thermo Fisher Scientific Inc., QIAGEN, Abbott, Danaher Corporation, Seimens Healthineers, Diasorin S.p.A, BD, GE Healthcare, QuantuMDx Group Ltd., BIOMÉRIEUX, SDI Diagnostics, COSMED srl, Seegene Inc., CAREstream Medical Ltd., Bird Healthcare, visby medical, Vitalograph, Bio-Rad Laboratories, Inc., and others.

5. Which region has the highest share in the global respiratory disease testing market?

North America is expected to dominate the overall respiratory disease testing market during the forecast period, 2024 to 2030. This is due to the growing prevalence of respiratory diseases in the region. Additionally, increasing risk factors associated with respiratory disorders, the presence of robust research and development initiatives, and a highly viable market in terms of product development, and launches are some of the key factors driving the growth of the respiratory disease testing market in North America.